|
BTG2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 7.21060000041795E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.78830000036245E-07 |
| Normal-vs-Stage2 |
1.72580000001865E-06 |
| Normal-vs-Stage3 |
7.45929999990125E-08 |
| Normal-vs-Stage4 |
3.6753000000056E-06 |
| Stage1-vs-Stage2 |
2.667400E-01 |
| Stage1-vs-Stage3 |
2.975800E-02 |
| Stage1-vs-Stage4 |
2.791000E-01 |
| Stage2-vs-Stage3 |
5.512800E-01 |
| Stage2-vs-Stage4 |
8.311200E-01 |
| Stage3-vs-Stage4 |
7.882000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.17899999996229E-06 |
| Normal-vs-AfricanAmerican |
5.603700E-03 |
| Normal-vs-Asian |
1.339360E-03 |
| Caucasian-vs-AfricanAmerican |
6.116600E-01 |
| Caucasian-vs-Asian |
6.059400E-01 |
| AfricanAmerican-vs-Asian |
9.794200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.43279999981405E-08 |
| Normal-vs-Female |
5.47640000014837E-08 |
| Male-vs-Female |
1.313950E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.53268999999456E-05 |
| Normal-vs-Age(41-60Yrs) |
1.30849999724347E-08 |
| Normal-vs-Age(61-80Yrs) |
7.54019999771316E-08 |
| Normal-vs-Age(81-100Yrs) |
4.761600E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.653830E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.330400E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.313400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.620200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.817200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.528800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.476930E-03 |
| Classical-VS-Follicular |
7.392300E-02 |
| Classical-VS-Other |
4.107000E-01 |
| Classical-VS-Normal |
1.68109999999499E-05 |
| Tall-VS-Follicular |
2.253400E-01 |
| Tall-VS-Other |
2.588000E-01 |
| Tall-VS-Normal |
9.60320001297532E-09 |
| Follicular-VS-Other |
6.939000E-01 |
| Follicular-VS-Normal |
3.77440000032259E-07 |
| Other-VS-Normal |
1.555870E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.5570999995228E-07 |
| Normal-vs-N1 |
3.57990000000585E-05 |
| N0-vs-N1 |
5.888400E-01 |
|
|
